- Open Access
Multiplex ligation-dependent probe amplification and array comparative genomic hybridization analyses for prenatal diagnosis of cytogenomic abnormalities
© Xu et al.; licensee BioMed Central Ltd. 2014
Received: 27 July 2014
Accepted: 3 November 2014
Published: 9 December 2014
The aims of this study were to evaluate the clinical utility of multiplex ligation-dependent probe amplification (MLPA) and array comparative genomic hybridization (aCGH) analyses on prenatal cases and to review prenatal ultrasound findings of cytogenomic syndromes.
Of the 54 prenatal cases analyzed, cytogenomic abnormalities were characterized in 14 cases. In four fetuses with abnormal ultrasound findings, a 40.701 Mb duplication of 8q22.3-q24.3 and a 23.839 Mb deletion of 7q33-q36.3 derived from a paternal balanced translocation, a de novo 13.062 Mb deletion of 11q24.1-q25 for Jacobsen syndrome, a de novo 19.971 Mb deletion of 7q11.23-q21.3 for type 1 split-hand/foot malformation (SHFM1), and a de novo 28.909 Mb duplication of 3q21.1-q25.1 were detected. A 699.8 Kb deletion at 5p15.33 for Cri du Chat syndrome was confirmed in a fetus with abnormal MLPA result. A fetus with abnormal maternal screening was detected with a de novo distal 1.747 Mb duplication at 2q37.1-q37.2 and a 6.664 Mb deletion at 2q37.2-q37.3. Of the eight cases referred by history of spontaneous abortions, derivative chromosomes 11 from paternal carriers of a balanced 8q/11q and a 10q/11q translocation were noted in two cases, simple aneuploids of trisomy 2 and trisomy 21 were seen in three cases, and compound aneuploids of two or three chromosomes were found in three cases. Post-test genetic counseling was performed with detailed genomic information and well characterized postnatal syndromic features.
These results demonstrated that coupling MLPA screening and aCGH analysis are a cost-effective approach to detect cytogenomic abnormalities in a prenatal setting. The aCGH analysis provided not only genomic maps of breakpoints and gene content of imbalanced regions but also better inference of related phenotypes for genetic counseling. Prenatal ultrasound findings reported in the literature for Jacobsen syndrome, SHFM and Cri du Chat syndrome were summarized for use as diagnostic references.
Prenatal genetic diagnosis has been driven by innovative technologies and accumulated clinical knowledge. Since late 1970s, invasive amniocentesis of amniotic fluid (AF) and chorionic villus sampling (CVS) procedures, non-invasive maternal serum screening, and high resolution ultrasound examination have been introduced and become the standard of care in prenatal diagnosis. The major clinical indications for prenatal diagnosis include advanced maternal age (AMA) for increased risk of Down syndrome, abnormal maternal serum screening (aMSS), abnormal ultrasound (aUS) findings, family history (FH) of chromosomal or genetic disorders, history of spontaneous abortion (hSAB), and recently integrated maternal serum fetal DNA sequencing for aneuploidy screening -. In a retrospective study, advances in maternal serum screening and ultrasonography have resulted in more than 50% decline in AF and CVS procedures, while the diagnostic yield for chromosomal abnormalities increased from 2% in 1991 to 7% in 2002 . A recent report of prenatal cases from 2007 to 2009 showed an abnormality detection rate of 10.2% for numerical chromosomal abnormalities and 1.9% for structural chromosomal abnormalities . However, routine prenatal cytogenetic analysis has two obvious limitations: the low analytical resolution of about 5–10 megabase (Mb) by the Giemsa banding and the long turn-around time due to the in vitro cell culture procedures. Various DNA-based molecular approaches have been introduced to provide rapid prenatal screening and diagnosis. Fluorescence in situ hybridization (FISH) using labeled DNA probes in the size of 100–800 kilobase (Kb) has enhanced the analytical resolution and allowed rapid screening of locus-specific numerical aberrations. A multiplex FISH panel with differentially labeled probes was developed for prenatal screening of common aneuploidies of chromosomes X, Y, 13, 18 and 21 . Quantitative fluorescence-polymerase chain reaction (QF-PCR) had been introduced for prenatal diagnosis of fetal aneuploids ,. Multiplex ligation-dependent probe amplification (MLPA) was validated as a rapid, cost-effective and multi-allelic approach for prenatal screening of common aneuploids, recurrent genomic disorders and subtelomeric imbalances -. For pediatric patients with intellectual and developmental disabilities, genome-wide array comparative genomic hybridization (aCGH) using synthesized oligonucleotides has been validated and recommended as first tier genetic testing -. Extended application of this aCGH analysis on prenatal diagnosis has been effective in defining gene content of chromosomal imbalances and in detecting genomic disorders and cryptic aberrations -. However, there are technical challenges and clinical concerns for rapid replacement of prenatal cytogenetics with genomic analysis . In the technical front, proper DNA extraction avoiding maternal cell contamination, cautious on confined-placental mosaicism, and timely confirmatory and follow up parental analyses need to be considered. While in the clinical part, the benefit, limitations and possible outcomes should be discussed in pre- and post-testing genetic consulting. In this study, we present an approach coupling MLPA and aCGH analyses for prenatal detection of cytogenomic abnormalities. Fourteen prenatal cases with chromosomal rearrangements and submicroscopic abnormalities were defined and genetic counseling was conducted with more detailed genomic characteristics. We also reviewed prenatal ultrasound findings reported in literature for Jacobsen syndrome, SHFM1 and Cri du Chat syndrome.
Summary of Prenatal Clinical Features and Abonormalities Detected by Karyotyping, MPLA and aCGH*
Case no. [sample]
MLPA (Region-Specific Assay, rsa)
aCGH findings (hg18)
arr 8q22.3q24.3(105,474,143-146,175,291)x3, 7q33q36.3(134,972,470-158,811,468) x1
arr 2q37.2(234,210,736-235,957,912)x3, 2q37.3(236,012,851-242,677,269)x1
arr 8q24.13q24.3(125,657,117-146,265,147)x3, 11q23.3q25(116,350,093-134,432,412)x1
arr 10q26.13q26.3(126,217,300-135,284,309)x3, 11q24.1q25(122,322,510-134,432,465)x1
rsa X(P095)x2,Y(P095)x1, 21(P095)x3,22p13(P036)×3, 22q13.3(P036)×3
rsa X(P095)x2,Y(P095)x1, 10p15(P036)×3,10q26.3(P036)×3
rsa 21(P095)x3,8p23.3(P036)×3, 8q24.3(P036)×3
Amniocentesis was performed because of multiple malformations detected at 12 weeks of gestation. The ultrasonographic examination revealed fetal growth retardation, bilateral cleft lip and palate, right-sided aortic arch, multiple cystic hypoplasias. MLPA analysis indicated a subtelomeric duplication of 8q and a subtelomeric deletion of 7q. Chromosome analysis performed on cultured amniocytes showed a derivative chromosome 7 from a translocation between chromosomal bands 7q33 and 8q22.3. Further aCGH analysis revealed a 40.701 Mb duplication of 8q22.3-q24.3 (105,474,143-146,175,291) including genes from DPYS to ZNF16 and a 23.839 Mb deletion of 7q33-q36.3 (134,972,470-158,811,468) including genes from NUP205 to VIPR2. Follow up chromosome analysis on both parents detected the father as a carrier of a balanced translocation of 7q33/8q22.3.
Amniocentesis was performed at 23 weeks gestation because of ultrasound detected anomalies of an increased nuchal translucency (NT) and fetal growth retardation. MLPA performed on DNA extracted from non-cultured aminiocytes showed normal result. Further aCGH analysis of DNA from cultured amniocytes revealed a 28.909 Mb duplication of 3q21.1-q25.1 (124,410,610-153,319,948) including genes from SEC22A to SUCNR1. Chromosome analysis performed on cultured amniocytes confirmed the 3q21.1-q25.1 duplication. Parental chromosome analysis showed normal results. The parents elected pregnancy termination.
Amniocentesis was performed because of abnormal MLPA result of a deletion in the Cri du Chat region. Ultrasound examination at 18 weeks gestation found a normal result. Chromosome analysis of cultured amniocytes showed a normal result. Follow-up aCGH analysis revealed a 699.8 Kb deletion at 5p15.33 (711,361-1,411,206) including genes TPPP, ZDHHC11, BRD9, TRIP13, NKD2, SLC12A7, SLCA19, SLC6A18, TERT and CLPTM1L. The parents decided to continue the pregnancy and the fetus was delivery at term. Follow up communication to the mother suggested that the girl appeared normal at age of two years.
Amniocentesis was performed at 22 gestational weeks because of the abnormal second trimester screening result suggesting an increased risk for Down’s syndrome. MLPA performed on DNA extracted from non-cultured aminiocytes detected a subtelomeric deletion of 2q and chromosome analysis performed on cultured amniocytes revealed a 2q37 deletion. Further aCGH analysis of DNA from cultured amniocytes revealed a 1.747 Mb duplication at 2q37.1-q37.2 (234,210,736-235,957,912) including genes from UGT1A8 to SH3BP4 and a 6.664 Mb deletion at 2q37.2-37.3 (236,012,851-242,677,269) including genes from AGAP1 to PDCD1. Parental chromosome analysis showed normal results. The parents elected pregnancy termination.
CVS was performed because of hSAB and absence of fetal heart by ultrasound examination at 8 weeks gestation. MLPA analysis indicated a subtelomeric duplication of 10q and a subtelomeric deletion of 11q. Further aCGH analysis revealed a 9.067 Mb duplication of 10q26.13-q26.3 (126,217,300-135,284,309) including genes from LHPP to SYCE1 and a 12.110 Mb deletion of 11q24.1-q25 (122,322,510-134,432,465) including genes from C11orf63 to B3GAT. Follow up parental chromosome analysis found that the father is a carrier for a balanced translocation between chromosomal bands 10q26 and 11q24.
CVS was performed because of hSAB for the six patients. MLPA analyses detected XXY sex chromosome and three copies of chromosomes 21 and 22 in patient 9, XXY sex chromosome and three copies of chromosome 10 in patient 10, three copies of chromosomes 8 and 21 in patient 11, three copies of chromosome 2 in patients 12 and 13, and three copies of chromosome 21 in patient 14. Follow up aCGH analyses confirmed the MLPA results for all six patients and ruled out other submicroscopic abnormalities. Parental chromosome analyses on all of them found normal results.
Abnormal ultrasound findings in Jacobsen syndrome, SHFM and Cri du Chat sydnrome
Abnormal ultrasound findings
Nuchal thickening (NT)
McClelland, 1998 
Unilateral duplex renal system, pyelectasis, orofacial clefts.
Chen, 2001 
Fetal biometry ~22 wks, short femurs and humeri, overlapping toes
Chen, 2004 (2 cases) 
Cerebral ventricular dilatation
Bohem, 2006 
Hydronephrosis, hypoplastic lefft hear syndrome, 'keel-shaped' skull of trigonocepholy.
Foley, 2007 
Single ventricle, single atrium, atrioventricular valve
This report (case#2)
NT 1.0 mm, single digit hand, two-digit split-foot.
Haak, 2001 
Irregular shaped hands with missing digits, clawlike feet.
Ram, 2009 
Bilateral Cleft Lip/palate, median clefts of both hands and feet, oligodactyly.
c.598A>G TP63 gene
Simonazzi, 2012 
7 bilateral anomalies (3 both hands and foot, 2 only in hands and 2 only foot) and 3 unilateral anomalies in hands.
22q11.2 del, 7q31 del, 8 unknown
Lu, 2014 (10 cases) 
Split hand/split foot, umbilical cord cysts.
This report (case#3)
Cri du Chat
Pleural effusion, ascites, skin edema, hypoplastic cerebellum, large ventricular septal defect, cystic lesion in nuchal skin edema.
Aoki, 1999 
Moderate biparietal cerebral ventriculomegaly
Stefanou, 2002 
Chen, 2004 
Bakkum 2005 
Absent nasal bone
Sherer, 2006 
NT 1.6 mm, hypoplastic nasal bone (1.8 mm)
Teoh, 2009 
This report (case#5)
The clinical impact from recognized compound segmental deletion and duplication in cases 1, 6, 7 and 8 should be interpreted with caution in a prenatal setting. The detected paternal carrier of a balanced translocation in cases 7 and 8 provides genetic explanation for the recurrent spontaneous abortions. Actually, parental chromosome analyses for case 7 were performed three times in other hospitals; the reciprocal translocation in the father, denoted as t(10;11)(q26.13;q24.1), was missed due to the similar size and light G-band pattern of the translocated segments. This case indicated that genomic characterization of prenatal segmental imbalances could facilitate karyotyping recognition of hidden subtelomeric rearrangements. Interestingly both cases 7 and 8 showed absence of fetal heart at ultrasound examination which could be explained partially by the shared 11q deletion for Jacobsen syndrome and partially by compound effect from other segmental imbalances. The other six patients (cases 9–14) with hSAB were detected with simple and compound aneuploids but no other pathogenic copy number variants. Parental chromosome analyses performed on these six families showed normal findings.
Technically, FISH and QF-PCR have been used for rapid screening of prenatal aneuploidy but these methods were limited to a few chromosomal loci -. MLPA using aneuploidy probe mix (P095), subtelomeric probe mixes (P036 and P070) and microdeletion syndromes probe mix (P245) has been a robust method for rapid prenatal screening of aneuploidy, unbalanced subtelomeric rearrangements and recurrent microdeletions. The turn-around-time of MLPA screening is usually within one to three days. However, MLPA screening lacks the genome-wide coverage and cannot detect copy number changes outside the represented regions. For example, MLPA missed the deletion of 7q11.23-q21.3 in case 3 and duplication of 3q21.1-q25.1 in case 4. In cases 6, MLPA detected the 2q deletion but missed the coexisted 2q duplication. Therefore, MLPA should be used as a rapid and cost-effective screening for common aneuploids, subtelomeric rearrangements and known genomic disorders. Follow up genome-wide aCGH analysis is strongly recommended to define genomic coordinates for MLPA and karyotype detected abnormalities and to rule out other copy number aberrations. Recently, genomic SNP array has been proposed as a gold standard for prenatal diagnosis of fetal ultrasound abnormalities , but rapid replacement of prenatal cytogenetic analysis raised serious concerns . One major concern is the detection of variants of unknown significance (VUS), which can complicate the genetic counseling and add unnecessary anxiety to the pregnant women. Of the 54 prenatal cases analyzed by aCGH in this report, no VUS was detected. The other concern is the high cost of aCGH analysis, which likely explains the low acceptance rate for further aCGH analysis in our experience. It is worth noted that aCGH analysis also has its limitations in the detection of polyploidy, balanced chromosomal rearrangements, inversions and low level mosaicism. Although routine chromosome analysis can neither provide the genomic coordinates for chromosomal abnormalities nor detect the submicroscopic copy number changes, karyotyping is still the gold standard for prenatal diagnosis of chromosome aneuploids and structural rearrangements.
In summary, aCGH is effective in characterizing chromosomal and submicroscopic imbalances. It has been estimated that approximately 10% of pregnancies with ultrasound-detected structural anomalies and normal cytogenetic findings had genomic abnormalities, and 30% of these abnormalities were recurrent genomic disorders . The workflow of MLPA, karyotyping and aCGH analysis as shown in Figure 1 represents a robust and cost-effective approach for prenatal diagnosis of chromosomal aneuploids, subtelomeric rearrangements and genomic imbalances. The MLPA screening results guide focused chromosome analysis of aneuploids and subtelomeric rearrangements and aCGH analysis for fine mapping of breakpoints and gene content of imbalanced regions. Further aCGH analysis on prenatal cases with indicative clinical findings can help to detect or rule out other genomic imbalances. This integrated approach can significantly reduce the number of cases for aCGH and thus reduce the overall cost of prenatal diagnosis.
For the past two years, of the 2509 cases analyzed by karyotyping and MLPA, numerical chromosomal and structural abnormalities were noted in 106 (4.2%) and 102 cases (4.1%), respectively. Of cases with structural chromosomal abnormalities detected by karyotyping, suspected genomic abnormalities by MLPA, and indicative findings of aUS, aMSS, FH and hSAB, pre-test genetic counseling with detailed information about the advantages and limitations of aCGH was provided. Post-test genetic counseling for cases with abnormal aCGH results was provided with detailed genomic findings and evidence-based interpretation. This study was reviewed and approved by the Ethics Committee of Shenzhen Maternity and Child Healthcare Hospital and participated patients also provided written informed consent.
Karyotyping and MLPA analysis
Chromosome analysis was performed on G-band metaphases prepared from cultured cells of amniotic fluid (AF), chorionic villus samples (CVS), and peripheral blood lymphocytes according to the laboratory’s standard protocols. Twenty metaphases were examined for each sample. Genomic DNA was extracted from AF and CVS using the chelex-100 (Bio-Rad Laboratories Inc, Hercules, CA, USA). The DNA concentration was measured using the NanoDrop spectrophotometer (ND-2000, Thermo Fisher Scientific Inc., Waltham, MA, USA). For each MLPA assay, 100 ng of DNA was used following the manufacturer’s protocols. The MLPA assays included the SALSA MLPA P095 aneuploidy probe mix for the detection of aberrant copy number of human chromosomes 13, 18, 21, X and Y, the P036/P070 human subtelomeric probe mix for the detection of deletions and duplications of subtelomeric region of each chromosome, the P245 microdeletion probe mix for 22 regions of 1p36 (OMIM#607872), 2p16 (OMIM#612513), 2q23.1 (OMIM#156200), 2q33 (OMIM#612313), 3q29 (OMIM#609425), 4p16.3 (OMIM#194190), 5p15.2 (OMIM #123450), 5q35 (OMIM#117550), 7q11.23 (OMIM#194050), 8q24.1 (OMIM#150230), 9q22.3, 10p14 (OMIM#601362), 15q11.2 (OMIM#176270, OMIM#105830), 15q24 (OMIM#613406), 16p13.3 (OMIM#180849), 17p13.3 (OMIM#607432, OMIM#247200) 17p11.2 (OMIM#182290), 17q11.2 (OMIM#162200), 17q21 (OMIM#610443), 22q11.2 (OMIM#188400), 22q13.3 (OMIM#606232) and Xq28 (OMIM#312750).
Array comparative genomic hybridization (aCGH)
For each sample, 2 μg of genomic DNA was prepared following the manufacturers protocol for the Agilent Human Genome CGH microarray 60 K kit (SurePrint G3 Human CGH 8x60K Microarray Kit) or 180 K kit (SurePrint G3 Human CGH 4×180K Microarray Kit) (Agilent Technologies Inc, Santa Clara, CA, USA). This validated aCGH procedure can achieve 99% sensitivity and 99% specificity with an analytical resolution determined by a sliding window of five to seven contiguous oligonucleotides . The base pair designation was based on the NCBI36/hg18 assembly of the UCSC Human Genome browser (http://genome.ucsc.edu/).
Written informed consent was obtained from the patient for participation in this study and publication of this report and any accompanying images.
We would like to thank Dongmei Wang, Autumn Diadamo and Shengli Li for their technical support and helpful discussions, Audrey Meusel for proofreading and editing this manuscript, and also extend our appreciation to the patients and their family members who participated in this study. This work was supported in part by Shenzhen Science and Technology Key Program Grant 201001016 (JX).
- Los FJ, van Den Berg C, Wildschut HI, Brandenburg H, den Hollander NS, Schoonderwaldt EM, Pijpers L, Jan H, Galjaard R, Van Opstal D: The diagnostic performance of cytogenetic investigation in amniotic fluid cells and chorionic villi. Prenat Diagn 2001, 21: 1150–1158. 10.1002/pd.194View ArticlePubMedGoogle Scholar
- Benn PA, Egan JF, Fang M, Smith-Bindman R: Changes in the utilization of prenatal diagnosis. Obstet Gynecol 2004,103(6):1255–1260. 10.1097/01.AOG.0000127008.14792.14View ArticlePubMedGoogle Scholar
- Li P, Pomianowski P, DiMaio MS, Florio JR, Rossi MR, Xiang B, Xu F, Yang H, Geng Q, Xie J, Mahoney MJ: Genomic characterization of prenatally detected chromosomal structural abnormalities using oligonucleotide array comparative genomic hybridization. Am J Med Genet 2011,155A(7):1605–1615. 10.1002/ajmg.a.34043View ArticlePubMedGoogle Scholar
- Xu Z, Xie J, Meng J, Li P, Pan X, Zhou Q: Non-invasive prenatal diagnosis: a comparison of cell free fetal DNA (cffDNA) based screening and fetal nucleated red blood cell (fnRBC) initiated testing. N A J Med Sci 2013,6(4):194–199. 10.7156/najms.2013.0604194View ArticleGoogle Scholar
- Ried T, Landes G, Dackowski W, Klinger K, Ward DC: Multicolor fluorescence in situ hybridization for the simultaneous detection of probe sets for chromosomes 13, 18, 21, X and Y in uncultured amniotic fluid cells. Hum Mol Genet 1992,1(5):307–313. 10.1093/hmg/1.5.307View ArticlePubMedGoogle Scholar
- Adinolfi M, Pertl B, Sherlock J: Rapid detection of aneuploidies by microsatellite and the quantitative fluorescent polymerase chain reaction. Prenat Diagn 1997,17(13):1299–1311. 10.1002/(SICI)1097-0223(199712)17:13<1299::AID-PD297>3.0.CO;2-HView ArticlePubMedGoogle Scholar
- Kooper AJ, Faas BH, Feenstra I, de Leeuw N, Smeets DF: Best diagnostic approach for the genetic evaluation of fetuses after intrauterine death in first, second or third trimester: QF-PCR, karyotyping and/or genome wide SNP array analysis. Mol Cytogenet 2014,7(1):6. 10.1186/1755-8166-7-6PubMed CentralView ArticlePubMedGoogle Scholar
- Slater HR, Bruno DL, Ren H, Pertile M, Schouten JP, Choo KH: Rapid, high throughput prenatal detection of aneuploidy using a novel quantitative method (MLPA). J Med Genet 2003,40(12):907–912. 10.1136/jmg.40.12.907PubMed CentralView ArticlePubMedGoogle Scholar
- Ahn JW, Ogilvie CM, Welch A, Thomas H, Madula R, Hills A, Donaghue C, Mann K: Detection of subtelomere imbalance using MLPA: validation, development of an analysis protocol, and application in a diagnostic centre. BMC Med Genet 2007, 8: 9. 10.1186/1471-2350-8-9PubMed CentralView ArticlePubMedGoogle Scholar
- Kjaergaard S, Sundberg K, Jørgensen FS, Rohde MD, Lind AM, Gerdes T, Tabor A, Kirchhoff M: Diagnostic yield by supplementing prenatal metaphase karyotyping with MLPA for microdeletion syndromes and subtelomere imbalances. Prenat Diagn 2010,30(10):995–999. 10.1002/pd.2604View ArticlePubMedGoogle Scholar
- Konialis C, Hagnefelt B, Sevastidou S, Karapanou S, Pispili K, Markaki A, Pangalos C: Uncovering recurrent microdeletion syndromes and subtelomeric deletions/duplications through non-selective application of a MLPA-based extended prenatal panel in routine prenatal diagnosis. Prenat Diagn 2011,31(6):571–577. 10.1002/pd.2750View ArticlePubMedGoogle Scholar
- Xiang B, Li A, Valentin D, Novak N, Zhao H-Y, Li P: Analytical and clinical validity of whole genome oligonucleotide array comparative genomic hybridization for pediatric patients with mental retardation and developmental delay. Am J Med Genet 2008,146A(15):1942–1954. 10.1002/ajmg.a.32411View ArticlePubMedGoogle Scholar
- Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, et al.: Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010,86(5):749–764. 10.1016/j.ajhg.2010.04.006PubMed CentralView ArticlePubMedGoogle Scholar
- Xu F, Li L, Schulz VP, Gallager PG, Xiang B, Zhao HY, Li P: Cytogenomic mapping and bioinformatic mining reveal interacting brain expressed genes for intellectural disabilities. Mol Cytogenet 2014,7(1):4. 10.1186/1755-8166-7-4PubMed CentralView ArticlePubMedGoogle Scholar
- Coppinger J, Alliman S, Lamb AN, Torchia BS, Bejjani BA, Shaffer LG: Whole-genome microarray analysis in prenatal specimens identifies clinically significant chromosome alterations without increase in results of unclear significance compared to targeted microarray. Prenat Diagn 2009,29(12):1156–1166. 10.1002/pd.2371View ArticlePubMedGoogle Scholar
- Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, Savage M, Platt LD, Saltzman D, Grobman WA, Klugman S, Scholl T, Simpson JL, McCall K, Aggarwal VS, Bunke B, Nahum O, Patel A, Lamb AN, Thom EA, Beaudet AL, Ledbetter DH, Shaffer LG, Jackson L: Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012,367(23):2175–2184. 10.1056/NEJMoa1203382PubMed CentralView ArticlePubMedGoogle Scholar
- Filges I, Kang A, Klug V, Wenzel F, Heinimann K, Tercanli S, Miny P: Array comparative genomic hybridization in prenatal diagnosis of first trimester pregnancies at high risk for chromosomal anomalies. Mol Cytogenet 2012,5(1):38. 10.1186/1755-8166-5-38PubMed CentralView ArticlePubMedGoogle Scholar
- Wei Y, Xu F, Li P: Technology-driven and evidence-based genomic analysis for integrated pediatric and prenatal genetics evaluation. J Genet Genomics 2013,40(1):1–12. 10.1016/j.jgg.2012.12.004View ArticlePubMedGoogle Scholar
- Ye M, Coldren C, Liang X, Mattina T, Goldmuntz E, Benson DW, Ivy D, Perryman MB, Garrett-Sinha LA, Grossfeld P: Deletion of ETS-1, a gene in the Jacobsen syndrome critical region, causes ventricular septal defects and abnormal ventricular morphology in mice. Hum Mol Genet 2010,19(4):648–656. 10.1093/hmg/ddp532PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang A, Zheng C, Hou M, Lindvall C, Li KJ, Erlandsson F, Björkholm M, Gruber A, Blennow E, Xu D: Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in Cri du Chat syndrome. Am J Hum Genet 2003,72(4):940–948. 10.1086/374565PubMed CentralView ArticlePubMedGoogle Scholar
- Hodge JC, Lawson-Yuen A, Stoler JM, Ligon AH: Molecular studies of segmental aneusomy: FISHing for the atypical cry in del(5)(p15.3). Cytogenet Genome Res 2007,119(1–2):15–20. 10.1159/000109613View ArticlePubMedGoogle Scholar
- McClelland SM, Smith AP, Smith NC, Gray ES, Diack JS, Dean JC: Nuchal thickening in Jacobsen syndrome. Ultrasound Obstet Gynecol 1998,12(4):280–282. 10.1046/j.1469-0705.1998.12040280.xView ArticlePubMedGoogle Scholar
- Chen CP, Chern SR, Tzen CY, Lee MS, Pan CW, Chang TY, Wang W: Prenatal diagnosis of de novo distal 11q deletion associated with sonographic findings of unilateral duplex renal system, pyelectasis and orofacial clefts. Prenat Diagn 2001,21(4):317–320. 10.1002/pd.42View ArticlePubMedGoogle Scholar
- Chen CP, Chern SR, Chang TY, Tzen CY, Lee CC, Chen WL, Chen LF, Wang W: Prenatal diagnosis of the distal 11q deletion and review of the literature. Prenat Diagn 2004,24(2):130–136. 10.1002/pd.802View ArticlePubMedGoogle Scholar
- Boehm D, Laccone F, Burfeind P, Herold S, Schubert C, Zoll B, Männer J, Pauer HU, Bartels I: Prenatal diagnosis of a large de novo terminal deletion of hromosome 11q. Prenat Diagn 2006,26(3):286–290. 10.1002/pd.1408View ArticlePubMedGoogle Scholar
- Foley P, McAuliffe F, Mullarkey M, Reardon W: Antenatal diagnosis of deletion chromosome 11(q23-qter) (Jacobsen syndrome). Clin Dysmorphol 2007,16(3):177–179. 10.1097/MCD.0b013e3281e668bfView ArticlePubMedGoogle Scholar
- Haak MC, Cobben JM, van Vugt JMG: First trimester diagnosis of split hand/foot by transvaginal ultrasound. Fetal Diagn Ther 2001, 16: 146–149. 10.1159/000053899View ArticlePubMedGoogle Scholar
- Ram KT, Goffman D, Ilagan J, Dar P: First-trimester diagnosis of familial split-hand/split-foot malformation. J Ultrasound Med 2009,28(10):1397–1400.PubMedGoogle Scholar
- Simonazzi G, Miccoli S, Salfi N, Bonasoni MP, Bocciardi R, Ravazzolo R, Seri M, Curti A, Pilu G, Rizzo N, Turchetti D: A novel p63 mutation in a fetus with ultrasound detection of split hand/foot malformation. Prenatal Diagn 2012,32(3):296–298. 10.1002/pd.2932View ArticleGoogle Scholar
- Lu J, Vaidya N, Meng H, Dai Q, Romine LE, Jones MC, Pretorius DH: Prenatally diagnosed fetal split-hand/foot malformations often accompany a spectrum of anomalies. J Ultrasound Med 2014,33(1):167–176. 10.7863/ultra.33.1.167View ArticlePubMedGoogle Scholar
- Aoki S, Hata T, Hata K, Miyazaka K: Antenatal sonographic features of cri-du-chat syndrome. Ultrasound Obstet Gynecol 1999,13(3):216–221. 10.1046/j.1469-0705.1999.13030216.xView ArticlePubMedGoogle Scholar
- Stefanou EGG, Hanna G, Foakes A, Crocker M, Fitchett M: Prenatal diagnosis of cri du chat (5p-) syndrome in association with isolated moderate bilateral ventriculomegaly. Prenat Diagn 2002, 22: 64–66. 10.1002/pd.243View ArticlePubMedGoogle Scholar
- Chen CP, Lee CC, Chang TY, Town DD, Wang W: Prenatal diagnosis of mosaic distal 5p deletion and review of literature. Prenat Diagn 2004, 24: 50–57. 10.1002/pd.794View ArticlePubMedGoogle Scholar
- Bakkum JN, Watson WJ, Johansen KL, Brost BC: Prenatal diagnosis of Cri du Chat syndrome with encephalocele. Am J Perinatol 2005,22(7):351–352. 10.1055/s-2005-871656View ArticlePubMedGoogle Scholar
- Sherer DM, Eugene P, Dalloul M, Khoury-Collado F, Abdelmalek E, Kheyman M, Osho JA, Abulafia O: Second-trimester diagnosis of Cri du Chat (5p–) syndrome following sonographic depiction of an absent fetal nasal bone. J Ultrasound Med 2006, 25: 387–388.PubMedGoogle Scholar
- Teoh XH, Tan TY, Chow KK, Lee IW: Prenatal diagnosis of cri-du-chat syndrome: importance of ultrasonographical markers. Sigapore Med J 2009,50(5):e181-e184.Google Scholar
- Leung KY, Maclachlan NA, Sepulveda W: Prenatal diagnosis of ectrodactyly: the ‘lobster claw’ anomaly. Ultrasound Obstet Gynecol 1995, 6: 443–446. 10.1046/j.1469-0705.1995.06060443.xView ArticlePubMedGoogle Scholar
- Stoll C, Wiesel A, Queisser-Luft A, Froster U, Bianca S, Clementi M: EUROSCAN study group: Evaluation of the prenatal diagnosis of limb reduction deficiencies. Prenat Diagn 2000, 20: 811–818. 10.1002/1097-0223(200010)20:10<811::AID-PD927>3.0.CO;2-JView ArticlePubMedGoogle Scholar
- Srebniak MI1, Boter M, Oudesluijs GO, Cohen-Overbeek T, Govaerts LC, Diderich KE, Oegema R, Knapen MF, van de Laar IM, Joosten M, Van Opstal D, Galjaard RJ: Genomic SNP array as a gold standard for prenatal diagnosis of foetal ultrasound abnormalities. Mol Cytogenet 2012,5(1):14. 10.1186/1755-8166-5-14PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.